Parabilis Medicines, a Cambridge, Massachusetts–based clinical-stage biopharmaceutical company, has raised $305 million in an oversubscribed Series F financing to support the continued development of its cancer pipeline. The company is focused on targeting historically undruggable cancer drivers using its proprietary Helicon peptide platform. Parabilis Medicines operates from Cambridge and is building therapies aimed at both rare and common tumors.

The financing was co-led by RA Capital Management, Fidelity Management & Research Company, and Janus Henderson Investors. New investors joining the round include Frazier Life Sciences, Soleus Capital, and a life science–dedicated investment fund. Existing investors also participated heavily, including venBio Partners, Cormorant Asset Management, ARCH Venture Partners, GV, General Catalyst, Invus, and Foresite Capital, among others. The round was completed at an increased valuation compared to Parabilis’s prior financing.

The new capital will primarily support clinical development of FOG-001, also known as zolucatetide, Parabilis’s lead investigational therapy and the first direct inhibitor of the β-catenin and TCF interaction. The company plans to progress the drug toward a registrational trial in desmoid tumors while continuing evaluation across a broader range of genetically simple and complex tumor types. Funding will also be used to advance Parabilis’s discovery pipeline, including its prostate cancer programs, and to further expand the capabilities of its Helicon platform.

Parabilis Chairman, CEO, and President Mathai Mammen said the financing strengthens the company’s ability to advance zolucatetide across multiple tumor types while continuing to build a differentiated pipeline aimed at biology that has remained out of reach for decades. Investors echoed this view, noting that Parabilis’s Helicon technology offers a new way to address intracellular targets that traditional drug approaches have failed to reach.

The financing follows encouraging preliminary data presented in late 2025 from an ongoing Phase 1/2 trial of zolucatetide. Early results showed single-agent activity across several Wnt/β-catenin–driven tumor types, including desmoid tumors, which have received Fast Track designation from the U.S. Food and Drug Administration. Parabilis plans to share additional clinical data in 2026 while continuing to expand the application of its Helicon platform beyond its lead program.

SimpleClosure, founded in 2023, has raised just over $20 million from investors including Infinity Ventures, TTV Capital, Anthemis, The LegalTech Fund, and Carta. The company's founder and CEO, Dori Yona, came up with the concept after experiencing the complexity of shutting down a company.

SimpleClosure is expanding its vision with the launch of Asset Hub, a marketplace designed to help founders recover value from their assets, such as source code, operational data, domain names, and equipment.

According to Yona, the company has seen strong year-over-year growth in startup shutdown activity, with 2.6x more companies closing in Q1 2026 compared to Q1 2025. The Asset Hub aims to capture the value of these assets, which often evaporate during the shutdown process.

X-energy has raised over $1 billion in capital investment through its IPO and a simultaneous private investment.

This funding will be used to hasten the placement of its Xe-100 advanced small modular reactors as the world searches for clean, sustainable baseload power.

The Xe-100 reactor utilises "pebbles", graphite spheres containing thousands of "TRISO" particles, which are essentially indestructible and capable of withstanding high temperatures.

X-energy intends to use the proceeds to fund the final stages of licensing, supply chain development, and the construction of its TRISO-X fuel fabrication facility.

The company is currently managing a pipeline of over 11 gigawatts of new nuclear capacity through various commercial partnerships, including a project with Dow Inc. to provide high-temperature steam and power for industrial processes.

Cloneable, a startup that uses AI to shadow human experts in heavy industries such as energy and replicate their specialized workflows into autonomous agents, has raised $4.6 million in seed funding. Congruent Ventures led the raise, which included participation from First In, Overline, Bull City Venture Partners, and St. Elmo Venture Capital.

The idea for Cloneable traces back to a bottleneck its founders encountered years earlier while working in the field. The startup's founders realized that heavy industries face a “knowledge crisis” as experienced workers retire faster than they can be replaced.

Cloneable aims to capture and preserve that kind of institutional knowledge. The funding will also support expansion into infrastructure-heavy industries such as public utilities, vegetation management, construction, rail, mining, agriculture, and manufacturing.

The company claims that a process that typically takes a human engineer eight hours can be completed by a Cloneable agent in under two minutes.

INVIA has raised $1.2 million in funding, according to the company’s latest update. The investor backing the round was not disclosed.

Details about the company’s core operations were not outlined in the announcement, though the funding suggests early-stage activity.

The round comes at a time when smaller funding deals continue across emerging startups, particularly at the pre-seed and seed stages.

Further specifics on INVIA’s product, market focus, and use of funds were not shared.

In a move to revolutionize industrial maintenance, Edmund, a Czech startup, has landed €2.5 million in funding. This investment, led by FORWARD.one and backed by University2Ventures and T, underscores the potential of AI in transforming the factory floor.

The funding will likely be used to further develop Edmund's AI-powered debugging platform, designed to streamline troubleshooting processes in industrial settings. By leveraging AI, Edmund's platform could significantly reduce downtime and increase overall efficiency.

Edmund's approach to industrial maintenance highlights a growing trend towards adopting AI-driven solutions in manufacturing. As factories become increasingly complex, the need for intelligent troubleshooting tools has never been more pressing.

FORWARD.one's involvement in the funding round suggests a strong belief in Edmund's technology and its potential impact on the industry. With the participation of University2Ventures and T, Edmund is well-positioned to capitalize on its innovative approach.

The application of AI in industrial maintenance is still a relatively new field, but one that holds immense promise. Edmund's success in securing funding is a testament to the viability of its solution and the interest it has generated among investors.

As Edmund moves forward with its plans, the focus will be on how effectively it can implement its AI-driven troubleshooting platform across various industrial settings. The potential for growth and the impact on the manufacturing sector are significant, making Edmund a startup to watch in the coming years.

With its innovative approach and newfound funding, Edmund is poised to make a meaningful difference in the world of industrial maintenance. The use of AI to enhance troubleshooting capabilities is a step towards a more efficient and productive factory floor, and Edmund is at the forefront of this change.

InfiniteWatch raised EUR 3.4 million in a pre-seed round. The deal was led by Base10 Partners. Sequoia, a16z scouts, Kfund, Kibo, and LifeX also invested. InfiniteWatch is a startup based in Madrid. It was founded in 2025. The company operates in Spain.